Overcoming obstacles to repurposing for neurodegenerative disease

Area of Science:

• Drug repurposing for neurodegenerative diseases
• Translational medicine
• Drug development policy

Background:

• Repurposing Food and Drug Administration (FDA)-approved drugs accelerates new treatments but faces commercial, regulatory, and reimbursement challenges.
• Neurodegenerative diseases like Alzheimer's and Parkinson's require innovative therapeutic strategies.
• Existing FDA-approved drugs offer a potential starting point for novel treatments.

Purpose of the Study:

• To convene stakeholders and understand perspectives on repurposing FDA-approved drugs for neurodegenerative diseases.
• To identify opportunities for philanthropy, industry, and government to address challenges in drug repurposing.
• To promote policy changes and develop funding strategies for repurposed drugs.

Main Methods:

• Convened an advisory panel with diverse stakeholders in October 2013.
• Gathered perspectives on the challenges and opportunities in drug repurposing for neurodegenerative diseases.
• Analyzed stakeholder input to formulate actionable recommendations.

Main Results:

• Identified significant commercial, regulatory, and reimbursement challenges.
• Highlighted the potential of philanthropy, industry, and government collaboration.
• Outlined strategies for policy changes and targeted funding.

Conclusions:

• Drug repurposing holds promise for accelerating neurodegenerative disease treatments.
• Addressing systemic challenges requires a multi-sectoral approach involving philanthropy, industry, and government.
• Strategic funding and policy reform are crucial to realizing the potential of repurposed FDA-approved drugs.